Sana Biotechnology, Inc. (SANA) stock
SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.85−0.03 (-1.60%)
Close on Nov 18, 2026Market cap $553.82MP/E –Yield –
Sana Biotechnology operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sana Biotechnology's operating cash flow for the twelve months ending Jun 30, 2026 was -$132.24M. For fiscal 2025 it was -$143.83M. The highest annual figure on record is -$85.52M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$143.83M | – |
| FY2024 | Dec 31, 2024 | -$223.15M | – |
| FY2023 | Dec 31, 2023 | -$253.58M | – |
| FY2022 | Dec 31, 2022 | -$290.05M | – |
| FY2021 | Dec 31, 2021 | -$251.05M | – |
| FY2020 | Dec 31, 2020 | -$137.98M | – |
| FY2019 | Dec 31, 2019 | -$85.52M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$32.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$37.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$32.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$33.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$48.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$47.16M | – |
| Q3 FY2024 | Sep 30, 2024 | -$51.82M | – |
| Q2 FY2024 | Jun 30, 2024 | -$58.54M | – |
| Q1 FY2024 | Mar 31, 2024 | -$65.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$51.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$63.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$58.80M | – |
| Q1 FY2023 | Mar 31, 2023 | -$79.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$76.07M | – |
| Q3 FY2022 | Sep 30, 2022 | -$64.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$71.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$77.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$110.10M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.49M | – |
| Q2 FY2021 | Jun 30, 2021 | -$40.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$49.91M | – |
| Q4 FY2020 | Dec 31, 2020 | -$37.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$37.51M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.55M | – |
See a number that looks wrong?